What changes we may expect in 2010 hypertension diagnosis and management: Insights from the european update document

Current Vascular Pharmacology

Volumn 8, Issue 6, 2010, Pages 788-791

  Mancia, Giuseppe ^a,b   Grassi, Guido ^a,b  

^a SAN GERARDO HOSPITAL   (Italy)

^b ISTITUTO AUXOLOGICO ITALIANO   (Italy)

Author keywords

Antihypertensive treatment; Blood pressure; Clinical trials; Control; Guidelines

Indexed keywords

ACETYLSALICYLIC ACID; ALISKIREN; ANGIOTENSIN RECEPTOR ANTAGONIST; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CALCIUM ANTAGONIST; DIURETIC AGENT; RAMIPRIL; TELMISARTAN;

ANTIHYPERTENSIVE THERAPY; ARTICLE; BLOOD PRESSURE MEASUREMENT; CARDIOVASCULAR RISK; CLINICAL PRACTICE; CLINICAL TRIAL; DIASTOLIC BLOOD PRESSURE; HIGH RISK PATIENT; HUMAN; HYPERTENSION; SYSTOLIC BLOOD PRESSURE;

EID: 78649372906     PISSN: 15701611     EISSN: None     Source Type: Journal    
DOI: 10.2174/157016110793563942     Document Type: Article

References (18)

1. 2003 European Society of Hypertension-European Society of Cardiology guidelines for the management of arterial hypertension. European Society of Hypertension-European Society of Cardiology Guidelines Committee. J Hypertens 2003; 21: 1011-1053
2. Mancia G, De Backer G, Dominiczak A, et al. Management of Arterial Hypertension of the European Society of Hypertension; European Society of Cardiology. 2007 Guidelines for the Management of Arterial Hypertension: The Task Force for the Management of Arterial Hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC). J Hypertens 2007; 25: 1105-1187
3. Yusuf S, Teo KK, Pogue J, Dyal L, et al.; ONTARGET Investigators. Telmisartan, ramipril, or both in patients at high risk for vascular events. N Engl J Med 2008; 358: 1547-1559
4. Yusuf S, Diener HC, Sacco RL, et al. PRoFESS Study Group. Telmisartan to prevent recurrent stroke and cardiovascular events. N Engl J Med 2008; 359: 1225-1237
5. Telmisartan Randomised AssessmeNt Study in ACE iNtolerant subjects with cardiovascular Disease (TRANSCEND) Investigators. Effects of the angiotensin-receptor blocker telmisartan on cardiovascular events in high-risk patients intolerant to angiotensinconverting enzyme inhibitors: a randomised controlled trial. Lancet 2008; 372: 1174-1183
6. Patel A, MacMahon S, Chalmers J, et al.; ADVANCE Collaborative Group. Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes. N Engl J Med 2008; 358: 2560-2572
7. Gerstein HC, Miller ME, Byington RP, et al.; Action to Control Cardiovascular Risk in Diabetes Study Group. Effects of intensive glucose lowering in type 2 diabetes. N Engl J Med 2008; 358: 2545-2559
8. Beckett NS, Peters R, Fletcher AE, et al.; HYVET Study Group. Treatment of hypertension in patients 80 years of age or older. N Engl J Med 2008; 358: 1887-1898
9. Jamerson K, Weber MA, Bakris GL, et al.; ACCOMPLISH Trial Investigators. Benazepril plus amlodipine or hydrochlorothiazide for hypertension in high-risk patients. N Engl J Med 2008; 359: 2417-2428
10. Cirillo M, Lanti MP, Menotti A, et al. Definition of kidney dysfunction as cardiovascular risk factor: use of urinary albumin excretion and estimated glomerula filtration rate. Arch Intern Med 2008; 168: 617-624
11. Ruilope LM, Zanchetti A, Julius S, et al. prediction of cardiovascular outcome by estimated glomerular filtration rate and estimated creatinine clearance in the high-risk hypertension population of the VALUE trial. J Hypertens 2007: 25: 1473-1479
12. Tsioufis C, Vezali E, Tsiachris D, et al. Left ventricular hypertrophy vs. chronic kidney disease as predictors of cardiovascular events in hypertension: a Greek 6-year-follow-up study. J Hypertens 2009; 27: 744-752
13. Zanchetti A, Grassi G, Mancia G. When should antihypertensive drug treatment be initiated and to what levels should systolic blood pressure be lowered? a critical appraisal. J Hypertens 2009; 27: 923-934
14. Mancia G, Grassi G. Systolic and diastolic blood pressure control in antihypertensive drug trials. J Hypertens 2002; 20: 1461-1464
15. Mancia G, Parati G, Bilo G, et al. Assessment of long-term antihypertensive treatment by clinic and ambulatory blood pressure: data from the European Lacidipine Study on Atherosclerosis. J Hypertens 2007; 25: 1087-1094
16. Azizi M, Webb R, Nussberger J, Hollenberg NK. Renin inhibition with aliskiren: where are we now, and where are we going? J Hypertens 2006; 24: 243-256
17. Yusuf S, Pais P, Afzal R, et al.; Indian Polycap Study (TIPS). Effects of a polypill (Polycap) on risk factors in middle-aged individuals without cardiovascular disease (TIPS): a phase II, doubleblind, randomised trial. Lancet 2009; 373: 1341-1351
18. Yusuf S, Pais P, Afzal R, et al. Indian Polycap Study (TIPS). Effects of a polypill (Polycap) on risk factors in middle-aged individuals without cardiovascular disease (TIPS): a phase II, doubleblind, randomised trial. Lancet 2009; 373: 1341-1351.